Semaglutide — Peptide Glossary | RetatrutideCompare

A GLP-1 receptor agonist developed by Novo Nordisk. FDA-approved as Ozempic (type 2 diabetes) and Wegovy (obesity). Widely studied in metabolic research. A single agonist compared to Retatrutide's triple agonism.
Category: Research Peptides & Compounds